Aspire Biopharma Holdings, Inc. (ASBP) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In USD
Address
23150 Fashion Drive
Estero, FL 33928
United States of America (the)
Phone
415 592 7399
Website
Sector
Healthcare
Industry
Biotechnology
Employees
2
First IPO Date
February 20, 2025
| Name | Title | Pay | Year Born |
| Kraig T. Higginson | Interim Chief Executive Officer, President & Executive Chairman of the Board | 342,500 | 1956 |
| Ernest J. Scheidemann Jr. | Chief Financial Officer | 320,000 | 1961 |
| Stephen E. Quesenberry | General Counsel & Corporate Secretary | 0 | 1963 |
Aspire Biopharma Holdings, Inc. is an emerging pharmaceutical enterprise dedicated to pioneering and commercializing innovative sublingual drug delivery systems within the United States. Its flagship product, Instaprin, is an advanced sublingual aspirin formulation known for being soluble, pH neutral, and rapidly absorbed, making it effective for both cardiovascular emergencies and general pain management. The company is diligently developing a diverse pipeline of orally dissolving formulations. This includes a melatonin-based sleep aid, essential vitamins (D, E, and K), testosterone, and semaglutide. Furthermore, Aspire Biopharma is extending its sublingual development efforts to various therapeutic areas, such as anti-nausea treatments, antipsychotic medications, erectile dysfunction drugs, and seizure control therapies, among others. They are also exploring caffeine products, including a formulation for a single-dose sublingual pre-workout supplement. Established in 2021, the firm's main operational base is situated in Estero, Florida.